Translational studies: Drug candidates and preclinical testing

Nai Ki MAK, Hong Lok LUNG, K. F. Hui, A. K.S. Chiang, Fei Fei Liu

Research output: Chapter in book/report/conference proceedingChapterpeer-review

1 Citation (Scopus)

Abstract

Nasopharyngeal carcinoma (NPC) is an Epstein-Barr-associated malignancy. Both the host and viral factors are known to contribute to the oncogenic development of NPC. NPC has a wide mutational diversity and many signaling pathways are known to be activated in the tumor cells. However, molecularly targeted therapeutic agents licensed for the treatment of NPC are still not available. This review will focus on several major areas related to the development of potential molecularly targeted drug candidates for the future treatment of NPC. These include the genetics-guided drug development and the therapeutic targeting of the viral factors in the tumors.

Original languageEnglish
Title of host publicationNasopharyngeal Carcinoma
Subtitle of host publicationFrom Etiology to Clinical Practice
PublisherElsevier
Pages109-127
Number of pages19
ISBN (Electronic)9780128149362
ISBN (Print)9780128149379
DOIs
Publication statusPublished - 1 Jan 2019

Scopus Subject Areas

  • Economics, Econometrics and Finance(all)
  • Business, Management and Accounting(all)

User-Defined Keywords

  • Epstein-Barr virus
  • Genetics-guided drugs
  • Nasopharyngeal carcinoma
  • Signaling pathways
  • Therapeutic target
  • Virus

Fingerprint

Dive into the research topics of 'Translational studies: Drug candidates and preclinical testing'. Together they form a unique fingerprint.

Cite this